Thyroglobulin Autoantibodies as Surrogate Biomarkers in the Management of Patients with Differentiated Thyroid Carcinoma

被引：24

作者：

Feldt-Rasmussen, U. ^{[1
]}

Verburg, F. A. ^{[2
]}

Luster, M. ^{[3
]}

Cupini, C. ^{[4
]}

Chiovato, L. ^{[5
]}

Duntas, L. ^{[6
]}

Elisei, R. ^{[7
]}

Rimmele, H. ^{[8
]}

Seregni, E. ^{[9
]}

Smit, J. W. A. ^{[10
]}

Theimer, C. ^{[11
]}

Giovanella, L. ^{[12
,13
,14
]}

机构：

[1] Univ Copenhagen, Rigshosp, Dept Med Endocrinol & Metab, DK-2100 Copenhagen, Denmark

[2] Univ Hosp Aachen, Dept Nucl Med, Aachen, Germany

[3] Univ Hosp Marburg, Dept Nucl Med, Marburg, Germany

[4] Azienda Osped Univ Pisana, Endocrine Outpatient Clin, I-56100 Pisa, Italy

[5] Univ Pavia Hosp, Fdn Salvatore Maugeri IRCCS, Dept Internal Med & Endocrinol, I-27100 Pavia, Italy

[6] Univ Athens, Sch Med, Evgenid Hosp, Endocrine Unit, GR-11527 Athens, Greece

[7] Univ Hosp Pisa, Dept Endocrinol, Pisa, Italy

[8] Self Help Org Thyroid Canc Patients Bundesverband, Berlin, Germany

[9] Ist Tumori, Dept Endocrinol, Milan, Italy

[10] Radboud Univ Nijmegen Med Ctr, Dept Endocrinol, Nijmegen, Netherlands

[11] Thermo Fisher Sci Inc, BRAHMS GmbH, Hennigsdorf, Berlin, Germany

[12] Oncol Inst So Switzerland, Dept Nucl Med, Bellinzona, Switzerland

[13] Oncol Inst So Switzerland, PET Ctr, Bellinzona, Switzerland

[14] Ente Osped Cantonale, Dept Lab Med EOLAB, Bellinzona, Switzerland

来源：

CURRENT MEDICINAL CHEMISTRY | 2014年 / 21卷 / 32期

关键词：

Anti-thyroglobulin autoantibodies; thyroglobulin; antibody interference; differentiated thyroid cancer; follow-up; ANTITHYROGLOBULIN ANTIBODY-LEVELS; REFERENCE MATERIAL CRM-457; SERUM THYROGLOBULIN; PROGNOSTIC-SIGNIFICANCE; HETEROPHILE ANTIBODIES; SEQUENTIAL-CHANGES; MASS-SPECTROMETRY; NEGATIVE PATIENTS; CLINICAL UTILITY; CANCER;

D O I：

10.2174/0929867321666140826120844

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Differentiated thyroid cancer is a rare malignancy, but leaves numerous survivors for life-long follow-up. The cornerstone in current guidelines for follow-up is by measuring the thyroid specific tumour marker, thyroglobulin in serum. Most patients can be followed by this method, but some thyroid cancer patients have antithyroglobulin antibodies in serum, both at diagnosis and after treatment, where follow-up is commenced. These antibodies interfere technically in the immunological methods for measuring thyroglobulin, and the antithyroglobulin antibody positive patients are thus eliminated from following current guidelines. In recent years studies have indicated that following the concentration of antithyroglobulin antibodies in serum may be a surrogate marker for recurrence of the thyroid carcinoma. This has recently resulted in publication of an expert position paper, providing a flow scheme for these particular patients. The current review summarises the literature which is the basis for the paper.

引用

页码：3687 / 3692

页数：6

共 42 条

[1]

[Anonymous], 2003, THYROID, V13, P3

[2]

Clark O.H., 1990, THYROID GLAND, P537

[3]

Can we interpret serum thyroglobulin results? [J].